- Home
- PLX vs PROF Comparison
PLX vs PROF Comparison
Compare PLX & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- PROF
- Stock Information
- Founded
- PLX 1993
- PROF N/A
- Country
- PLX United States
- PROF Canada
- Employees
- PLX N/A
- PROF N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- PROF Medical/Dental Instruments
- Sector
- PLX Health Care
- PROF Health Care
- Exchange
- PLX Nasdaq
- PROF Nasdaq
- Market Cap
- PLX 127.4M
- PROF 134.3M
- IPO Year
- PLX 1998
- PROF N/A
- Fundamental
- Price
- PLX $1.91
- PROF $4.09
- Analyst Decision
- PLX Strong Buy
- PROF Strong Buy
- Analyst Count
- PLX 1
- PROF 1
- Target Price
- PLX $15.00
- PROF $11.00
- AVG Volume (30 Days)
- PLX 705.4K
- PROF 181.3K
- Earning Date
- PLX 11-13-2025
- PROF 11-06-2025
- Dividend Yield
- PLX N/A
- PROF N/A
- EPS Growth
- PLX N/A
- PROF N/A
- EPS
- PLX 0.08
- PROF N/A
- Revenue
- PLX $61,948,000.00
- PROF $11,840,000.00
- Revenue This Year
- PLX $14.53
- PROF $60.07
- Revenue Next Year
- PLX $75.77
- PROF $121.80
- P/E Ratio
- PLX $24.60
- PROF N/A
- Revenue Growth
- PLX 62.79
- PROF 59.81
- 52 Week Low
- PLX $0.99
- PROF $3.76
- 52 Week High
- PLX $3.10
- PROF $9.17
- Technical
- Relative Strength Index (RSI)
- PLX 70.20
- PROF 35.14
- Support Level
- PLX $1.52
- PROF $3.76
- Resistance Level
- PLX $1.69
- PROF $4.69
- Average True Range (ATR)
- PLX 0.08
- PROF 0.19
- MACD
- PLX 0.03
- PROF -0.00
- Stochastic Oscillator
- PLX 91.67
- PROF 33.67
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.